Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of SSGJ-613 in Healthy Subjects
NCT05027373Phase 1Unknown
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Aug 2021
- Primary completion
- Apr 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SSGJ-613 in systemic juvenile idiopathic arthritis (SJIA) and periodic fever syndrome (6 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoints: Maximum Plasma Concentration up to 112 days, Time to Maximum Concentration up to 112 days and 7 more. Status: unknown.
02
Drugs
SSGJ-613
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)periodic fever syndrome
Beyond the preview
Go deeper on NCT05027373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027373.